 |
 Previous Article | Next Article 
Journal of Neuroscience, Vol 12, 4854-4866, Copyright © 1992 by Society for Neuroscience
Trigeminal and dorsal root ganglion neurons express CCK receptor binding sites in the rat, rabbit, and monkey: possible site of opiate- CCK analgesic interactions
JR Ghilardi, CJ Allen, SR Vigna, DC McVey and PW Mantyh
Molecular Neurobiology Laboratory, Veterans Administration Medical Center, Minneapolis, Minnesota 55417.
125I-Bolton-Hunter sulfated cholecystokinin-8 was used to localize and
characterize cholecystokinin (CCK) receptor binding sites in trigeminal and
dorsal root ganglia, and in the spinal cord of the rat, rabbit, and monkey.
In the rabbit and monkey, a substantial number, 90 +/- 21% and 24 +/- 8%,
respectively, of trigeminal and dorsal root ganglion neurons express CCK
binding sites. In the spinal cord, the highest concentration of CCK
receptors is found in laminae I and II, which is the major termination site
of dorsal root ganglia neurons expressing CCK receptor binding sites.
Neonatal capsaicin treatment of the rat results in a 70% decline in CCK
receptor binding sites in laminae I and II of the spinal cord, indicating
that dorsal root ganglia neurons are a major source of CCK receptors in the
spinal cord. Pharmacological experiments using selective CCK-A and CCK-B
receptor antagonists demonstrate that CCK-B is the prominent CCK receptor
subtype in trigeminal and dorsal root ganglia neurons in the rat, rabbit,
and monkey. In the rat and rabbit spinal cord, CCK-B binding sites are the
prominent subtype, whereas in the monkey cord, CCK-A is the prominent
receptor subtype. These results demonstrate that CCK-B receptors are
expressed by a substantial percentage of dorsal root ganglion neurons at
all spinal levels, and that CCK may antagonize opiate analgesia at the
level of the primary afferent neuron itself.
This article has been cited by other articles:
|
|
|
|
 
J. Y. Xie, D. S. Herman, C.-O. Stiller, L. R. Gardell, M. H. Ossipov, J. Lai, F. Porreca, and T. W. Vanderah
Cholecystokinin in the Rostral Ventromedial Medulla Mediates Opioid-Induced Hyperalgesia and Antinociceptive Tolerance
J. Neurosci.,
January 12, 2005;
25(2):
409 - 416.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Noble, S. A. Wank, J. N. Crawley, J. Bradwejn, K. B. Seroogy, M. Hamon, and B. P. Roques
International Union of Pharmacology. XXI. Structure, Distribution, and Functions of Cholecystokinin Receptors
Pharmacol. Rev.,
December 1, 1999;
51(4):
745 - 781.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Broberger, K. Holmberg, M. J. Kuhar, and T. Hokfelt
Cocaine- and amphetamine-regulated transcript in the rat vagus nerve: A putative mediator of cholecystokinin-induced satiety
PNAS,
November 9, 1999;
96(23):
13506 - 13511.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Szallasi and P. M. Blumberg
Vanilloid (Capsaicin) Receptors and Mechanisms
Pharmacol. Rev.,
June 1, 1999;
51(2):
159 - 212.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Rady, W. Lin, and J. M. Fujimoto
Pentobarbital Antagonism of Morphine Analgesia Mediated by Spinal Cholecystokinin
J. Pharmacol. Exp. Ther.,
March 1, 1998;
284(3):
878 - 885.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
Z.-Q. D. Xu, X. Zhang, S. Grillner, and T. Hokfelt
Electrophysiological studies on rat dorsal root ganglion neurons after peripheral axotomy: Changes in responses to neuropeptides
PNAS,
November 25, 1997;
94(24):
13262 - 13266.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Honoré, J. Buritova, M.-C. Fournié-Zaluski, B. P. Roques, and J.-M. Besson
Antinociceptive Effects of RB101, a Complete Inhibitor of Enkephalin-catabolizing Enzymes, Are Enhanced by a Cholecystokinin Type B Receptor Antagonist, as Revealed by Noxiously Evoked Spinal c-Fos Expression in Rats
J. Pharmacol. Exp. Ther.,
April 1, 1997;
281(1):
208 - 217.
[Abstract]
[Full Text]
|
|
|
|
|
